Tumor Suppressor Protein p14ARF
"Tumor Suppressor Protein p14ARF" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A gene product of the p16 tumor suppressor gene (GENES, P16). It antagonizes the function of MDM2 PROTEIN (which regulates P53 TUMOR SUPPRESSOR PROTEIN by targeting it for degradation). p14ARF is produced from the beta mRNA transcript of the p16 gene. The other gene product, produced from the alternatively spliced alpha transcript, is CYCLIN-DEPENDENT KINASE INHIBITOR P16. Both p16 gene products have tumor suppressor functions.
| Descriptor ID |
D025803
|
| MeSH Number(s) |
D12.776.167.600 D12.776.624.776.772
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Tumor Suppressor Protein p14ARF".
Below are MeSH descriptors whose meaning is more specific than "Tumor Suppressor Protein p14ARF".
This graph shows the total number of publications written about "Tumor Suppressor Protein p14ARF" by people in this website by year, and whether "Tumor Suppressor Protein p14ARF" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 2 | 2 |
| 1998 | 0 | 5 | 5 |
| 1999 | 0 | 5 | 5 |
| 2000 | 0 | 4 | 4 |
| 2001 | 1 | 10 | 11 |
| 2002 | 7 | 0 | 7 |
| 2003 | 6 | 0 | 6 |
| 2004 | 3 | 2 | 5 |
| 2006 | 4 | 6 | 10 |
| 2007 | 2 | 3 | 5 |
| 2010 | 3 | 0 | 3 |
| 2011 | 2 | 1 | 3 |
| 2012 | 2 | 1 | 3 |
| 2013 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tumor Suppressor Protein p14ARF" by people in Profiles.
-
Potentially functional variants of p14ARF are associated with HPV-positive oropharyngeal cancer patients and survival after definitive chemoradiotherapy. Carcinogenesis. 2014 Jan; 35(1):62-8.
-
Genetic variants in p53-related genes confer susceptibility to second primary malignancy in patients with index squamous cell carcinoma of head and neck. Carcinogenesis. 2013 Jul; 34(7):1551-7.
-
Significance of MDM2 and P14 ARF polymorphisms in susceptibility to differentiated thyroid carcinoma. Surgery. 2013 May; 153(5):711-7.
-
Genetic variation in MDM2 and p14ARF and susceptibility to salivary gland carcinoma. PLoS One. 2012; 7(11):e49361.
-
SINE retrotransposons cause epigenetic reprogramming of adjacent gene promoters. Mol Cancer Res. 2012 Oct; 10(10):1332-42.
-
Recognition of nonkeratinizing morphology in oropharyngeal squamous cell carcinoma - a prospective cohort and interobserver variability study. Histopathology. 2012 Feb; 60(3):427-36.
-
Ink4a and Arf are crucial factors in the determination of the cell of origin and the therapeutic sensitivity of Myc-induced mouse lymphoid tumor. Oncogene. 2012 Jun 07; 31(23):2849-61.
-
Invasion precedes tumor mass formation in a malignant brain tumor model of genetically modified neural stem cells. Neoplasia. 2011 Sep; 13(9):784-91.
-
The ARF tumor suppressor regulates bone remodeling and osteosarcoma development in mice. PLoS One. 2010 Dec 30; 5(12):e15755.
-
p14ARF genetic polymorphisms and susceptibility to second primary malignancy in patients with index squamous cell carcinoma of the head and neck. Cancer. 2011 Mar 15; 117(6):1227-35.